title: Engineering peptide inhibitors to overcome PDZ binding promiscuity.
authors.affiliation: Institute of Medical Immunology, Charité-Universitätsmedizin Berlin, Hessische Strasse 3-4, 10115 Berlin, Germany.
authors.forename: Lars
authors.initials: L
authors.lastname: Vouilleme
authors.forename: Patrick R
authors.initials: PR
authors.lastname: Cushing
authors.forename: Rudolf
authors.initials: R
authors.lastname: Volkmer
authors.forename: Dean R
authors.initials: DR
authors.lastname: Madden
authors.forename: Prisca
authors.initials: P
authors.lastname: Boisguerin
mesh_terms: D048868:Adaptor Proteins, Signal Transducing; D000595:Amino Acid Sequence; D002352:Carrier Proteins / Q000235:genetics / Q000378:metabolism*; D003550:Cystic Fibrosis; D019005:Cystic Fibrosis Transmembrane Conductance Regulator; D015195:Drug Design; D000077614:Golgi Matrix Proteins; D006801:Humans; D008565:Membrane Proteins / Q000235:genetics / Q000378:metabolism*; D026901:Membrane Transport Proteins; D054731:PDZ Domains / Q000187:drug effects*; D019151:Peptide Library; D010455:Peptides / Q000138:chemical synthesis / Q000494:pharmacology*; D011485:Protein Binding / Q000187:drug effects; D015202:Protein Engineering
chemical_list: D048868:Adaptor Proteins, Signal Transducing; C505032:CFTR protein, human; D002352:Carrier Proteins; C434484:GOPC protein, human; D000077614:Golgi Matrix Proteins; D008565:Membrane Proteins; D026901:Membrane Transport Proteins; D019151:Peptide Library; D010455:Peptides; D019005:Cystic Fibrosis Transmembrane Conductance Regulator